Allergy Immunotherapy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Allergy immunotherapy (AIT), also called desensitisation or hyposensitisation, is the only disease-modifying treatment for IgE-mediated allergic diseases — capable of altering the underlying immunological abnormality rather than merely suppressing symptoms. While antihistamines, intranasal corticosteroids, and bronchodilators provide temporary symptomatic relief during allergen exposure, immunotherapy induces lasting changes in allergen-specific immune tolerance that persist for years after treatment completion.

The immunological mechanism of AIT involves progressive administration of increasing doses of the causative allergen, driving a shift from the Th2-dominated allergic immune response (characterised by IL-4, IL-5, IL-13 production and IgE antibody synthesis) toward a more balanced immune profile including regulatory T cell (Treg) induction producing IL-10 and TGF-beta, class-switching from IgE to IgG4 (blocking antibody), reduction in mast cell and basophil reactivity, and decreased eosinophil airway inflammation. These changes reduce both early-phase (acute) and late-phase (prolonged) allergic responses.

AIT is administered via two main routes. Subcutaneous immunotherapy (SCIT, allergy shots) involves weekly injections at the allergist's office during the build-up phase (typically 3-6 months to reach maintenance dose), followed by monthly maintenance injections for 3-5 years. Sublingual immunotherapy (SLIT) is administered as drops or dissolvable tablets placed under the tongue daily, with build-up and maintenance phases managed at home after initial training — significantly more convenient though with slightly lower efficacy than SCIT for some allergens.

AIT is supported by robust evidence from hundreds of randomised controlled trials and systematic Cochrane Reviews, and is endorsed by WHO, the European Academy of Allergy and Clinical Immunology (EAACI), and national allergy guidelines worldwide. It is the only treatment that can prevent the development of new allergen sensitisations and the progression from allergic rhinitis to asthma (demonstrated in the PAT trial and SCIT follow-up studies).

Allergic rhinitis (hay fever) is the most common indication for AIT. Both SCIT and SLIT are highly effective for seasonal allergic rhinitis (grass, tree, and weed pollens) and perennial allergic rhinitis (house dust mite, cat and dog dander, cockroach). Allergic asthma triggered by aeroallergens (house dust mite, grass pollen, alternaria) is treated with AIT — particularly HDM-SCIT or HDM-SLIT (Acarizax, ALK) — with evidence for improved asthma control and reduced inhaled corticosteroid doses. AIT is initiated only in well-controlled asthma (FEV1 above 70% predicted) due to anaphylaxis risk in uncontrolled asthma.

Venom immunotherapy (VIT) for Hymenoptera venom allergy (honeybee, yellow jacket, wasp) is the most immediately life-saving application of AIT — it reduces systemic sting reaction risk from 60% to less than 5% after a full VIT course in venom-allergic adults, enabling patients with previously life-threatening sting anaphylaxis to live without constant fear of a fatal reaction outdoors. Food allergy oral immunotherapy (food OIT) for peanut allergy (Palforzia, FDA-approved in 2020), milk, egg, and tree nuts represents the most rapidly growing AIT application, particularly in children, with peanut OIT achieving desensitisation (tolerating at least 600 mg peanut protein on challenge) in 67-80% of treated children.

Ideal candidates for aeroallergen immunotherapy are adults and children over 5 years with documented IgE-mediated allergy (positive skin prick test or specific IgE blood test confirming sensitisation to the causative allergen), moderate-to-severe allergic rhinitis causing significant quality-of-life impairment despite adequate pharmacotherapy, or allergic asthma with aeroallergen sensitisation. Patients who prefer a disease-modifying approach, or who wish to reduce long-term medication burden, are particularly well-suited to AIT.

Absolute contraindications to SCIT include: severe uncontrolled asthma (FEV1 below 70% predicted despite maximal therapy); active autoimmune disease; systemic immunosuppression; severe cardiovascular disease (beta-blocker use is a relative contraindication — beta-blockers impair adrenaline response to anaphylaxis); and pregnancy (new SCIT courses should not be started during pregnancy, though maintenance courses can often be continued with appropriate precautions). SLIT has a more favourable safety profile, allowing use during pregnancy maintenance in some cases. Patients must be able to commit to the 3-5 year treatment course — shorter courses have substantially inferior outcomes.

Subcutaneous immunotherapy (SCIT) follows a conventional build-up schedule of weekly injections increasing in dose over 3-6 months to the target maintenance dose, followed by monthly maintenance injections for 3-5 years. Cluster and rush protocols compress the build-up phase to weeks or days respectively by giving multiple injections per visit, allowing faster achievement of the maintenance dose at the cost of increased systemic reaction risk and mandatory pre-medication with antihistamines. All SCIT injections are administered in an allergy clinic with 20-30 minutes observation afterwards and emergency adrenaline available.

Sublingual immunotherapy (SLIT) uses standardised allergen extracts or dissolvable tablets (Grazax for grass pollen, Acarizax for house dust mite, Ragwizax for ragweed, Itulazax for tree pollen) taken daily at home after the first dose administered in clinic. The sublingual route exploits the tolerogenic oral mucosa rich in dendritic cells and regulatory T cells. SLIT tablets have an excellent safety profile with local oral pruritus and lip swelling as the most common reaction (10-15%), and systemic reactions are very rare. SLIT tablets have stronger evidence and regulatory approval compared to SLIT drops in many countries. Epicutaneous immunotherapy (EPIT) — a patch delivering allergen to the skin — is in late-stage development for peanut allergy and milk allergy, offering a non-injection, non-swallowing alternative particularly suitable for young children.

AIT produces substantial and durable clinical benefits. Cochrane Reviews of AIT for allergic rhinitis demonstrate 33% reduction in symptom scores and 38% reduction in rescue medication use compared to placebo — effects that are clinically meaningful and qualitatively superior to pharmacotherapy alone. Critically, these benefits persist for at least 3-7 years after completing a 3-5 year course, representing a fundamental disease modification rather than temporary suppression.

Venom immunotherapy achieves 95-97% protection against systemic sting reactions in venom-allergic adults — an outstanding outcome for a previously life-threatening allergy. Studies show that 5 years of VIT confers long-term tolerance that persists in 80-85% of patients for at least 10-15 years after completing treatment. The PAT (Preventive Allergy Treatment) trial demonstrated that 3 years of SCIT for grass and birch pollen in children with allergic rhinitis reduced the risk of developing asthma at 6-year follow-up by 45%, and prevented the development of new sensitisations — the only treatment proven to alter the natural history of allergic disease. For house dust mite asthma, a Cochrane Review of 61 trials showed significant reduction in asthma symptom scores and reduction in inhaled corticosteroid dose requirements.

Local injection site reactions — redness, swelling, and itching at the SCIT injection site lasting 1-24 hours — occur in 20-30% of injections and are managed with local antihistamine cream or ice. They are not a reason to stop treatment. Systemic reactions — affecting body systems beyond the injection site — occur in 0.1-0.5% of SCIT injections; most are mild-to-moderate (rhinitis flare, urticaria, asthma exacerbation) responding to antihistamines and bronchodilators. Severe anaphylaxis requiring adrenaline occurs in approximately 1 in 1,000,000 injections — this is why SCIT is always administered in a medical setting with 20-30 minutes post-injection observation.

Risk factors for severe systemic reactions include: poorly controlled asthma (the single most important risk factor); dosing errors; injection during a period of active allergic symptoms or respiratory infection; and vigorous exercise within 2 hours of injection. SLIT carries a much lower systemic reaction risk — anaphylaxis is extremely rare (estimated 1 in 100 million doses for standardised SLIT tablets). Patients on beta-blockers have impaired adrenaline response and increased risk of severe prolonged anaphylaxis — the risk-benefit of continuing SCIT versus switching to SLIT should be discussed with the allergist.

SCIT requires regular clinic attendance — weekly during build-up, monthly during maintenance — for the full 3-5 year course. Missed maintenance injections require dose adjustments to avoid increased systemic reaction risk when resuming: a gap of 2-8 weeks requires restart at the previous dose; longer gaps may require resuming at a reduced dose. Symptoms, peak flow (for asthmatic patients), and any systemic reactions are reviewed at each visit to adjust the protocol.

Annual review with the allergist assesses clinical response (symptom diary, medication use, quality-of-life questionnaire), serological response (decline in specific IgE, increase in specific IgG4), and spirometry for asthmatic patients. The decision to discontinue treatment at 3-5 years is made jointly after assessing the durability of clinical response and the allergen-specific antibody profile. After completing immunotherapy, patients typically need only occasional antihistamine or nasal spray use rather than daily medications. Patients who relapse significantly after completing a 3-5 year course may benefit from a second course or long-term maintenance extension.

SCIT in the United States costs $2,000-$5,000 annually for the complete programme (allergen extracts, injection fees, and clinic visits), totalling $6,000-$20,000 over a 3-5 year course. SLIT tablets (Grazax, Acarizax) cost $100-$150 per month in the US without insurance, totalling $3,600-$9,000 over a 3-year course. In the United Kingdom, NHS-funded immunotherapy for severe venom allergy and selected aeroallergen cases is available at specialist allergy centres; private SCIT costs £3,000-£6,000 per year.

Allergy immunotherapy at specialist clinics in India and Thailand is available at substantially lower cost. In India (Apollo Allergy and Immunology departments, AIIMS Delhi, Medanta), SCIT programmes cost $800-$2,000 per year including allergen preparation, all injections, and clinic visits. SLIT programmes cost $300-$600 per year. Specialist allergists in India are trained to international allergy board standards and use WHO-standardised allergen extracts. For patients with multiple allergies requiring multi-allergen immunotherapy, India offers exceptional value for comprehensive desensitisation, saving 60-75% over US rates.

Allergen avoidance is an important complementary strategy but rarely achieves adequate symptom control for most aeroallergens — house dust mite covers, pet removal, HEPA filters, and pollen-season strategies reduce allergen exposure but cannot eliminate it in most environments. Pharmacotherapy (intranasal corticosteroids, antihistamines, leukotriene receptor antagonists, and anti-IgE biologics) provides effective symptom control during allergen exposure without modifying the underlying disease. Biologics targeting the allergic inflammatory cascade — dupilumab (anti-IL-4/IL-13), omalizumab (anti-IgE), mepolizumab (anti-IL-5), benralizumab (anti-IL-5R) — provide excellent symptom control for severe allergic asthma and atopic dermatitis and represent an alternative for patients who are not suitable for or do not want immunotherapy. However, biologics require ongoing monthly or bimonthly injections indefinitely and do not modify the underlying disease — they are therefore complementary to, rather than replacing, immunotherapy's disease-modifying effect.